A Phase IIIb Study of Intermittent Versus Continuous Hormone Deprivation Treatment With ELIGARD
Status:
Completed
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
Phase IIIb, Open-label, randomized, controlled multi-centre study. Induction therapy phase
for 6 months where all subjects receive 2 ELIGARD depot injections. Those subjects with
hormone responsive prostate cancer will be randomized and will receive either intermittent or
continuous ELIGARD treatment for 36 months. Following this treatment period, subjects will
enter a long-term follow-up period for 48 months.